Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Decitabine
Drug: Venetoclax

First Posted Date: 2019-02-18

Last Posted Date: 2024-11-11

Lead Sponsor: University of Chicago

Target Recruit Count: 26

Registration Number: NCT03844815

Locations: 🇺🇸
University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

At Home Spirometry and Video Module Education for COPD Patients

Not Applicable

Completed

Conditions: COPD

Interventions: Other: BREATHES Program
Device: BREATHES SpiroPD or Propeller Health

First Posted Date: 2019-02-07

Last Posted Date: 2022-07-22

Lead Sponsor: University of Chicago

Target Recruit Count: 71

Registration Number: NCT03834350

Locations: 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States

Patient Outcomes Reporting for Timely Assessments of Life With Depression: PORTAL-Depression

Not Applicable

Completed

Conditions: Depressive Disorder, Major
Depression

Interventions: Other: CAT-DI monitoring via MyChart
Diagnostic Test: CAD-MDD/CAT-DI screening via MyChart
Diagnostic Test: CAD-MDD/CAT-DI screening during clinic visit
Other: PHQ-9 monitoring during clinic visits

First Posted Date: 2019-02-06

Last Posted Date: 2021-04-30

Lead Sponsor: University of Chicago

Target Recruit Count: 4161

Registration Number: NCT03832283

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Differential Responses to Drugs and Sweet Tastes

Phase 1

Completed

Conditions: Bipolar II Disorder

Interventions: Drug: d-amphetamine 10 mg oral capsule
Drug: d-amphetamine 20 mg oral capsule
Drug: Placebo oral capsule

First Posted Date: 2019-01-22

Last Posted Date: 2023-02-22

Lead Sponsor: University of Chicago

Target Recruit Count: 93

Registration Number: NCT03810703

Locations: 🇺🇸
University of Chicago Medical Center - Human Behavioral Pharmacology Lab, Chicago, Illinois, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Individual Differences in Drug Response

Early Phase 1

Completed

Conditions: Differential Female Response to Δ9-tetrahydrocannabinol (THC)

Interventions: Drug: dextrose
Drug: Dronabinol

First Posted Date: 2019-01-18

Last Posted Date: 2024-07-03

Lead Sponsor: University of Chicago

Target Recruit Count: 60

Registration Number: NCT03809546

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Developing a Mobile Method to Measure THC-induced Impairment

Early Phase 1

Completed

Conditions: Measuring THC-induced Cognitive Impairment Using a Mobile Application

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2019-01-15

Last Posted Date: 2019-01-15

Lead Sponsor: University of Chicago

Target Recruit Count: 48

Registration Number: NCT03804840

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Mood Effects of Serotonin Agonists

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lysergic Acid Diethylamide

First Posted Date: 2018-12-31

Last Posted Date: 2024-01-24

Lead Sponsor: University of Chicago

Target Recruit Count: 80

Registration Number: NCT03790358

Locations: 🇺🇸
Matthew Bona, Chicago, Illinois, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Effect of Stimulant Drugs on Social Perception

Phase 1

Completed

Conditions: Healthy
MDMA ('Ecstasy')

Interventions: Drug: 3,4-Methylenedioxymethamphetamine
Drug: methamphetamine

First Posted Date: 2018-12-31

Last Posted Date: 2024-01-05

Lead Sponsor: University of Chicago

Target Recruit Count: 36

Registration Number: NCT03790618

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD

Phase 1

Terminated

Conditions: Heart Failure
Gastrointestinal Bleeding

Interventions: Other: Placebo
Drug: Omega 3 fatty acids

First Posted Date: 2018-12-24

Last Posted Date: 2021-07-13

Lead Sponsor: University of Chicago

Target Recruit Count: 35

Registration Number: NCT03784963

Locations: 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States

Propagation ANalysis for Arrhythmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation (PANACEA-AF)

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2018-11-13

Last Posted Date: 2024-05-07

Lead Sponsor: University of Chicago

Target Recruit Count: 29

Registration Number: NCT03737838

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy